The episode explores how GLP-1 weight loss drugs like Ozempic and Wegovy, initially developed for diabetes, have evolved into a cultural and medical phenomenon, with expanding access due to competition, generics, and political intervention—though at great cost to Novo Nordisk, the pioneer
Sign up to read the full summary
Free AI-powered recaps of every episode, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.
Guest
Eshe Nelson
narrative on The Daily
Mentions
Books, people, and resources mentioned in this episode.
People
Companies
Products & Tools
Topics
Listen to This Episode
More from The Daily
Marriage and Sex in the Age of Ozempic: An Update
Congress Failed to Extend the Health Care Subsidies. Now What?
TrumpRx Opens for Business
Can We Reverse Aging?
R.F.K. Jr.’s Newest Mission: Getting Us Off Antidepressants
A Flood of New, Deadlier Drugs
Related episodes
From other shows on similar topics.
People are running their own experiments with GLP-1s — with stunning results
Apple News Today
What we got wrong about GLP-1s
Search Engine
Skinny and sad on GLP-1s
Today, Explained
Novo Nordisk's CEO Has a Comeback Plan
The Journal.
Reshaping the GLP-1 Economy: A Breaking Consumer Study
We Fixed It, You're Welcome
Rethinking addiction in the age of Ozempic
TED Radio Hour
Get summaries like this every morning.
Free AI-powered recaps of The Daily and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.